Document is current
Any future updates will be listed below
-
Authors
Duca, Franz
Poledniczek, Michael
Kronberger, Christina
Binder, Christina
Rettl, René
Camuz-Ligios, Luciana
Agis, Hermine
Koschutnik, Matthias
Donà, Carolina
Badr-Eslam, Roza
Beitzke, Dietrich
Loewe, Christian
Nitsche, Christian
Hengstenberg, Christian
Kastner, Johannes
Bergler-Klein, Jutta
Kammerlander, Andreas Anselm https://orcid.org/0000-0002-7632-9879
-
Funding
Funding for this research was provided by:
Pfizer Austria
- License Information
-
More Information
Article History
Received: 17 February 2025
Revised: 15 May 2025
Accepted: 2 June 2025
First Online: 16 July 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Franz Duca.
: The authors of this manuscript declare relationships with the following companies: F.D.: Speaker fees and congress support from Bayer, Novartis, Alnylam, Pfizer, and AOP, as well as research grants from the Austrian Society of Cardiology, Pfizer, and Bayer. CL is the Scientific Director of the European School of Radiology (ESOR). The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Franz Duca and Andreas A. Kammerlander have significant statistical expertise. Furthermore, no complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: In a prior study, we evaluated the prognostic significance of ECV quantification in ATTR CA, as well as light chain amyloidosis patients irrespective of treatment (Duca et al [ ]). The present study tests serial ECV quantification in a well-defined cohort consisting solely of patients on disease-modifying treatment.
:
